Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology
暂无分享,去创建一个
Tetsushi Sakuma | Yasuko Tsukazaki | Naoto Senda | Satoshi Abe | Kaoru Kobayashi | Mitsuo Oshimura | Yasuhiro Kazuki | Kan Chiba | M. Oshimura | M. Ikawa | Takashi Yamamoto | Y. Kazuki | S. Abe | K. Kazuki | S. Takehara | K. Chiba | Tetsushi Sakuma | Takashi Yamamoto | N. Senda | Masahito Ikawa | Shoko Takehara | Asami Oji | Kanako Kazuki | Kazuomi Nakamura | Azusa Okada | Kazuhisa Honma | Kazuomi Nakamura | K. Honma | Asami Oji | Yasuko Tsukazaki | Azusa Okada | Kaoru Kobayashi
[1] Yoshitaka Fujihara,et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA , 2013, Scientific Reports.
[2] I. Macphee. Pharmacogenetic biomarkers: cytochrome P450 3A5. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[3] Russ B Altman,et al. PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.
[4] Ronald N. Hines,et al. Developmental Expression of the Major Human Hepatic CYP3A Enzymes , 2003, Journal of Pharmacology and Experimental Therapeutics.
[5] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[6] T. Cresteil,et al. CYP3A5 mRNA Degradation by Nonsense-Mediated mRNA Decay , 2005, Molecular Pharmacology.
[7] S D Hall,et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. , 1994, Biochemical pharmacology.
[8] R. de Kanter,et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.
[9] T. Aoyama,et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.
[10] M. Oshimura,et al. Highly stable maintenance of a mouse artificial chromosome in human cells and mice. , 2013, Biochemical and biophysical research communications.
[11] H. Lerche,et al. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature , 2015, Clinical Pharmacokinetics.
[12] Frederick E. Petry,et al. Principles and Applications , 1997 .
[13] Su-Jun Lee,et al. Molecular functionality of CYP2C9 polymorphisms and their influence on drug therapy , 2014, Drug metabolism and drug interactions.
[14] T. Cresteil,et al. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. , 1997, European journal of biochemistry.
[15] M. Oshimura,et al. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. , 2013, Human molecular genetics.
[16] R. Eils,et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma , 2016, Nature Medicine.
[17] M. Ikawa,et al. CRISPR/Cas9 mediated genome editing in ES cells and its application for chimeric analysis in mice , 2016, Scientific Reports.
[18] T. Gaj,et al. Genome-Editing Technologies: Principles and Applications. , 2016, Cold Spring Harbor perspectives in biology.
[19] Tetsushi Sakuma,et al. Efficient TALEN construction and evaluation methods for human cell and animal applications , 2013, Genes to cells : devoted to molecular & cellular mechanisms.
[20] J. Azuma,et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.
[21] K. Thummel,et al. In vitro and in vivo drug interactions involving human CYP3A. , 1998, Annual review of pharmacology and toxicology.
[22] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[23] T Ishizaki,et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.
[24] D. Greenblatt,et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. , 2000, The Journal of pharmacology and experimental therapeutics.
[25] M. Oshimura,et al. Gender Difference of Hepatic and Intestinal CYP3A4 in CYP3AHumanized Mice Generated by a Human Chromosome-engineering Technique. , 2017, Drug Metabolism Letters.
[26] I. Cascorbi,et al. Functional Gene Variants of CYP3A4 , 2014, Clinical pharmacology and therapeutics.
[27] J. Beijnen,et al. Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam , 2009, Drug Metabolism and Disposition.
[28] M. McArthur,et al. Mouse models for the p53 R72P polymorphism mimic human phenotypes. , 2010, Cancer research.
[29] Ying Guo,et al. Genetic variation of CYP3A5 influences paclitaxel/carboplatin‐induced toxicity in Chinese epithelial ovarian cancer patients , 2016, Journal of clinical pharmacology.
[30] D. Satoh,et al. Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model , 2016, Scientific Reports.
[31] David A. Scott,et al. Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.
[32] M. Oshimura,et al. A novel and stable mouse artificial chromosome vector. , 2014, ACS synthetic biology.
[33] D. Greenblatt,et al. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[34] D. Hu,et al. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk , 2016, Drug metabolism reviews.
[35] R. Obach,et al. Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide) , 2014, Drug Metabolism and Disposition.
[36] J. Keith Joung,et al. 731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .
[37] Ann Daly,et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.